
Collegium Pharmaceutical, Inc.: updates and filings
Price
$25.43
November 16, 2026Market cap $807M
What Ploutos Investor adds for Collegium Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 19, 2026Material agreement endedForm8-K
- Oct 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 24, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Other material eventsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 5, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 30, 2026Financial statements and exhibits (amendment)Form8-K/A
- Jun 1, 2026Shares registered for employeesFormS-8
- Jun 1, 2026Shares registered for employeesFormS-8
- May 15, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 19, 2026 | 8-K | Material agreement ended | Document |
| Oct 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 24, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 8-K | Other material events | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 5, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 30, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Jun 1, 2026 | S-8 | Shares registered for employees | Document |
| Jun 1, 2026 | S-8 | Shares registered for employees | Document |
| May 15, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 20, 2003.
The full analysis
What do Collegium Pharmaceutical's filings show?
The filings are where every one of Collegium Pharmaceutical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.